Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Gastrointestinal 3Other hematologic neoplasm 2Tumor-Agnostic 1Thoracic 1Myeloid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 297Lung Neoplasms 195Colorectal Neoplasms 54Small Cell Lung Carcinoma 52Neoplasms 39Ovarian Neoplasms 38Melanoma 37Pancreatic Neoplasms 33Breast Neoplasms 31Neoplasm Metastasis 27Stomach Neoplasms 26Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Renal Cell 22Urinary Bladder Neoplasms 20Prostatic Neoplasms 20Esophageal Neoplasms 20Endometrial Neoplasms 20Head and Neck Neoplasms 19Triple Negative Breast Neoplasms 18Colonic Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Hepatocellular 16Mesothelioma 15Lung Diseases 13Sarcoma 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma, Malignant 12Adenocarcinoma of Lung 11Cholangiocarcinoma 10Rectal Neoplasms 9

Interventions

Monatide (IMS 3015) 1Biological Assay 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Thoracic × 30 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡